Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gloria Marti-Andres"'
Autor:
Ivan Martinez-Valbuena, Rafael Valenti-Azcarate, Irene Amat-Villegas, Irene Marcilla, Gloria Marti-Andres, Maria-Cristina Caballero, Mario Riverol, María-Teresa Tuñon, Paul E. Fraser, María-Rosario Luquin
Publikováno v:
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-18 (2021)
Abstract Protein misfolding diseases refer to a variety of disorders that develop as a consequence of the misfolding of proteins in various organs. The etiologies of Parkinson’s and Alzheimer’s disease remain unclear, but it seems that type two d
Externí odkaz:
https://doaj.org/article/7a977155641c4478bcefd6b211a7b1b5
Autor:
Tomaž Rus, Jernej Mlakar, Luka Ležaić, An Vo, Nha Nguyen, Chris Tang, Michele Fiorini, Elena Prieto, Gloria Marti‐Andres, Javier Arbizu, David Eidelberg, Maja Trošt
Publikováno v:
European journal of neurology, vol. 30, no. 4, pp. 1035-1047, 2023.
Background and purpose: Although sporadic Creutzfeldt–Jakob disease (sCJD) is a rare cause of dementia, it is critical to understand its functional networks as the prion protein spread throughout the brain may share similar mechanisms with other mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1376dd5f12510d235cb3c261d219d3a5
https://repozitorij.uni-lj.si/Dokument.php?id=167636&dn=
https://repozitorij.uni-lj.si/Dokument.php?id=167636&dn=
Autor:
Pablo Arrondo, Óscar Elía-Zudaire, Gloria Martí-Andrés, María A. Fernández-Seara, Mario Riverol
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-16 (2022)
Abstract Introduction People with subjective cognitive decline (SCD) report cognitive deterioration. However, their performance in neuropsychological evaluation falls within the normal range. The present study aims to analyse whether structural magne
Externí odkaz:
https://doaj.org/article/6d9147cfcb7b4014b4268f9567642939
Autor:
Gloria Martí-Andrés, Rayco Jiménez-Bolaños, José Matias Arbelo-González, Javier Pagonabarraga, Carmen Duran-Herrera, Rafael Valenti-Azcarate, Mª Rosario Luquin
Publikováno v:
Brain Sciences, Vol 9, Iss 10, p 272 (2019)
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which
Externí odkaz:
https://doaj.org/article/7302eefcca204779b4275d209dbd9efd